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Abstract 
Background: Ventricular assist devices (VADs) are an effective bridging or destination therapy 
for patients with advanced stage heart failure. These devices remain susceptible to adverse events 
including infection, bleeding, and thrombus; events linked to the foreign body response. Therefore, 
the biocompatibility of all biomaterials used is crucial to the success of medical devices. 
Methods: Biomaterials common in VADs - DLC: diamond-like carbon coated stainless steel; Sap: 
single-crystal sapphire; SiN: silicon nitride; Ti: titanium alloy; and ZTA: zirconia-toughened 
alumina - were tested for their biocompatibility through incubation with whole human blood for 2 
hours with mild agitation. Blood was then removed and used for: complete cell counts; leukocyte 
activation and death, and the production of key inflammatory cytokines. All were compared to 
time 0 and an un-exposed 2 hour sample. 
Results: Monocyte numbers were lower after exposure to DLC, SiN and ZTA and monocytes 
showed evidence of activation with DLC, Sap, and SiN. Neutrophils and lymphocytes were 
unaffected. 
Conclusions: This approach allows comprehensive analysis of the potential blood damaging 
effects of biomaterials. Monocyte activation by DLC, Sap, ZTA and SiN warrants further 
investigation linking effects on this cell type to unfavourable inflammatory/thrombogenic 
responses to VADs and other blood handling devices. 
Key Words 
Ventricular Assist Devices; Biomaterials; Human; Blood; Flow Cytometry   
3 
 
1. Introduction 
Ventricular assist devices (VADs) are a successful long-term therapy for end-stage heart failure 
[1, 2]. The use of biocompatible materials to construct these devices is essential. Blood contact 
with VADs is brief but frequent and the foreign body response towards these materials combined 
with heavy anti-coagulation likely contributes to VAD-associated clinical complications such as 
thrombosis, bleeding, and infection [3]. Surface properties of biomaterials drive the foreign body 
response beginning with protein adsorption, a complex process driven by different protein-surface 
forces such as surface energy, morphology, and ionic/electrostatic interactions [4]. The 
composition of the protein matrix adsorbed onto the material is highly variable but largely consists 
of the most abundant proteins in the blood: fibrinogen, albumin, and globulins. Platelet activation 
occurs through interaction with these proteins with fibrinogen in particular leading to platelet-
platelet aggregation [5] These immobilised platelets are then able to recruit and activate blood 
borne leukocytes, mainly neutrophils and monocytes, which contribute to the building of thrombus 
through adhesion whilst also releasing cytokines for further recruitment to the site [6]. Interactions 
of T cells with this biological surface build-up can cause activation-induced cell death resulting in 
defective cellular immunity and susceptibility to severe infections [7]. 
Adherence and activation of leukocytes at the biomaterial’s surface are well described for titanium, 
low density polyethylene (LDPE), Pellethane®, and polytetrafluoroethylene (PTFE) using in vitro 
models. This evidence is provided by changes in the expression of adhesion molecules such as 
decreased L-selectin (CD62L) and increased CD11b expression, an increase in inflammatory 
cytokine concentration (e.g. TNFα, MCP-1, IL-8), and the release of reactive oxygen species [8-
12].  A similar activation profile is also demonstrable in vivo after implantation of VADs, e.g. 
platelet-leukocyte aggregates and increased monocyte tissue factor expression [13-15]. Excessive 
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leukocyte activation could underpin a diminished immune response upon infection [16, 17]; and 
thrombotic leukocyte-derived microparticles [18, 19] might lead to stroke, embolism, or device 
replacement due to blockages.  
Titanium is the biomaterial most commonly used for the VAD body [20]; its resistance against 
fatigue and corrosion makes it durable for long-term implantation [21]. However, titanium can 
activate the coagulation system in vitro and thus be a thrombogenic material that activates 
leukocytes [22]. Other VAD components have been made from ruby alumina [23], sapphire [24], 
and zirconium [25] but the biocompatibility testing of these ceramic materials is limited to their 
applications as dental or joint implants [26, 27].  Silicon nitride could be a good candidate for use 
as a bearing due to its high strength and oxidation resistance [28] but its biocompatibility has been 
tested with osteoblasts [29] rather than blood cells. Coatings have been suggested as a solution for 
materials with desirable mechanical properties but poor biocompatibility. Diamond-like carbon 
(DLC) is a chemically inert nanocomposite coating with properties of natural diamond such as 
high hardness, low friction, and high corrosion resistance [30, 31]. DLC has been deemed 
biocompatible through prolonging clotting time, and suppressing platelet and complement 
activation [32]. 
This study aimed to evaluate the leukocyte response to biomaterials and test a methodological 
approach implementable within most device development laboratories that would enable rapid 
evaluation of multiple biomaterials. Biomaterials that are of interest to the development of 
cardiovascular devices such as VADs formed the focus of this investigation: diamond-like carbon 
coated stainless steel (DLC), single-crystal sapphire alumina (Sap), silicon nitride (SiN), titanium 
alloy Ti6Al4V (Ti), and zirconia-toughened alumina (ZTA). Biomaterials were exposed to whole 
blood rather than isolated cells or plasma to better mimic the clinical scenario [33].  
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2. Materials and methods 
2.1 Blood collection 
Peripheral blood was collected from healthy adult volunteers into lithium heparin (18 I.U. lithium 
heparin salt per mL; Vacutainer tubes; Greiner Bio-One, Stonehouse, UK). All blood samples were 
collected with informed written consent. This study was approved by Wales Research Ethics 
Committee 6 (13/WA/0190).  
2.2 Biomaterials 
Highly polished discs of DLC, Sap, SiN, Ti, and ZTA (Table 1; SAK Equipment Ltd, East Sussex, 
UK) were sonicated in 3% Neutracon® (Decon Laboratories Ltd., East Sussex, UK) at +40°C for 
10 min and then sonicated in warm, soapy dH2O for 3 min followed by a 3 min sonication in fresh 
dH2O. Discs were air-dried, sprayed with 70% denatured ethanol and left to dry on lint-free cloths. 
Polypropylene beads were soaked with 70% denatured ethanol for 30 min then rinsed in sterile 
PBS before use.  
2.3 Experimental model 
Twenty polypropylene beads (2-3 mm diameter) were placed in a circle in a 70 mm petri dish 
(Cole Parmer, London, UK). The biomaterials were then carefully balanced on top before the 
addition of blood (15 mL) (Supplementary Figure 1). Beads only served as a negative control. 
Dishes were incubated at +37°C on a shaker plate set to 50 rpm.  A time course was performed by 
sampling at 2, 4, and 8 h; the 2 h samples were deemed most appropriate to continue with for 
further analysis as longer incubation showed high levels of cell death and platelet 
activation/aggregation with little difference between biomaterials. As plasma-free haemoglobin 
(pfHB) can upregulate tissue factor expression on macrophages [34] haemolysis in all the samples 
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was measured using the Harboe assay [35] to check the condition of the red blood cells before 
progressing to further experiments.  
2.4 Complete cell counts 
Total and subset cell counts were measured in triplicate using an automated haematology analyser 
(CELL-DYN Ruby; Abbott Diagnostics, Berkshire, UK).  
2.6 Leukocyte activation, aggregation and death through flow cytometry 
Leukocyte activation and death 
Changes in leukocyte activation - decreased L-selectin (CD62L), increased CD11b, and increased 
fMLP receptor - were monitored using flow cytometry. These were measured as mean 
fluorescence intensity (CD62L) or percentage positive cells (CD11b, fMLP receptor) on CD15+ 
neutrophils, CD14+ monocytes, and CD3+ T cells. Changes in expression are presented as fold 
change compared to baseline (time 0 sample). Whole blood (20 µL) was stained for flow cytometry 
using standard protocols with various antibodies (Table 2). Red blood cells were lysed with 
EasyLyse (Dako, Ely, UK), and DRAQ7 (BioStatus, Leicester, UK) was used for viability 
monitoring without need for a wash step [36]. Whole blood stimulated with 10 ng/mL LPS for 4 
h at +37°C, 5% CO2-in-air as below was used as a positive control and unstained samples were 
used for gating purposes. Blood exposed to 1% Triton-X 100 (Fisher Scientific, Loughborough, 
UK) was used to set a gate for DRAQ7 positive cells. Single-stained AbC beads (Life 
Technologies, Paisley, UK) were used for compensation. Samples were acquired immediately 
(Navios flow cytometer, Beckman Coulter) using linear forward scatter (FSC) versus side scatter 
(SSC) scale, flow rate set to high, and stop gate on 10,000 CD15+ events which would allow for 
acquisition of approximately 5,000 total lymphocytes and 1,000 monocytes. Post-acquisition 
compensation and data analysis were performed using Kaluza 1.3 (Beckman Coulter).  
7 
 
Leukocyte-platelet aggregation 
The leukocyte-platelet aggregation assay was performed using CD15 and CD14 as above 
combined with 12.5 ng/µL CD41 (APC, clone P2, Beckman Coulter); CD41 is a platelet marker, 
CD15 a neutrophil marker and CD14 a monocyte marker – co-expression on an event identified 
using flow cytometry is indicative of aggregates containing these cells [37]. Samples were stained 
and lysed with a wash step included before running. Whole blood stimulated with 4 µM PMA for 
20 min was used as a positive control; tubes were run on a logarithmic scale with 10,000 CD15+ 
events as the stopping gate. 
2.7 Whole blood cultures  
Whole blood cultures (50 µL blood/150 µL RPMI 1640 containing 2 mM GlutaMax and 0.1 mM 
2-mercaptoethanol; Life Technologies) were left unstimulated or stimulated with 10 ng/mL E. coli 
OIII:B4 lipopolysaccharide (Ultrapure LPS, Invivogen, Toulouse, France) in a U-bottomed 96-
well plate. After 24 h incubation at +37°C, 5% CO2-in-air cell-free supernatants were harvested 
by centrifugation (+4°C, 515 x g, 7 min).  
2.8 L-selectin, cytokines and endotoxin levels 
Levels of plasma soluble L-selectin and IL-1β, TNFα, IL-6, and IL-8 in cell culture supernatants 
from whole blood cultures were measured using specific ELISAs as per the manufacturer’s 
instructions (DuoSet, R&D Systems, Oxford, UK). Presence of endotoxin was measured in 
unstimulated cell culture supernatants using the limulus amebocyte lysate LAL Chromogenic 
Endotoxin Quantitation Kit according to manufacturer’s instructions (Thermo Fisher Scientific, 
Loughborough, UK).  
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2. 9 Statistical analysis 
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) was used for all statistical 
analysis. Gaussian distributions were tested using D’Argostino & Pearson omnibus normality or 
Kolmogorov-Smirnov tests. Comparisons between baseline and biomaterials were analysed using 
one-way ANOVA or the Kruskal-Wallis non-parametric test. Repeated measures ANOVA was 
used for time course samples. Tukey or Dunn’s tests were applied post hoc. A p-value  0.05 was 
considered significant. 
3. Results 
3.1 Condition of blood 
Total erythrocyte counts in comparison to the baseline sample at time 0 (n = 16; Figure 1A) were 
not significantly affected by biomaterials. Concentrations of pfHB were not significantly higher 
than the baseline time 0 sample (n = 9; Figure 1B). 
3.2 Leukocyte cell counts 
Total leukocyte, neutrophil, and lymphocyte counts in comparison to the baseline sample at time 
0 (n=16; Figure 2A, B and D) were not significantly affected by biomaterials. Monocyte counts 
decreased significantly upon exposure to DLC (p = 0.018), SiN (p = 0.025), and ZTA (p= 0.009) 
(Figure 2C).  
3.3 Leukocyte activation and death 
Expression of CD62L (n = 9) on neutrophils (Figure 3Ai) and lymphocytes (Supplementary Figure 
S3) was not affected significantly by the biomaterials whereas expression of CD62L on monocytes 
(Figure 3Aii) decreased significantly upon exposure to DLC (p = 0.049), Sap (p = 0.009), and SiN 
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(p = 0.026). However, this was not detectable as soluble CD62L in the fluid phase (Supplementary 
Figure S4). 
The percentage of CD11bbright cells after exposure to biomaterials did not differ significantly in 
comparison to baseline for either neutrophils or monocytes (Figure 3Bi, Bii). CD11b is expressed 
on only 20-30% of lymphocytes so these data are not shown for CD3+ T cells [38].   
Incubation alone increased fMLP receptor expression by neutrophils and monocytes after 2 h 
incubation with no significant effects of the biomaterials (Figure 3Ci, Cii). Expression of fMLP 
receptor on T cells was not studied. 
Cell death was monitored throughout using DRAQ7 [36] and there was no significant effect of 
biomaterials exposure on cell death within any of the leukocyte subsets of interest (Figure 3Di-ii 
and Supplementary Figure S3B).  
3.4 Leukocyte-platelet aggregation 
Aggregation of leukocytes with platelets contributes to the build-up of thrombus on the surface of 
materials. Neutrophil-platelet and monocyte-platelet aggregates were elevated in comparison to 
the baseline time 0 sample in all biomaterials but this was not significant (Figure 4, n = 5).  
3.5 Cytokine production 
The effect of exposure to biomaterials on leukocyte functionality was considered by studying the 
response to the prototypic inflammatory stimuli LPS using whole blood cultures after exposure to 
biomaterials. LPS induced a significant increase in inflammatory cytokine levels in blood exposed 
to biomaterials as well as control blood in keeping with the expected effects of LPS [39]. Levels 
of LPS-stimulated pro-inflammatory cytokines IL-8 (Figure 5A; n = 7), IL-1β (Figure 5B; n = 7), 
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IL-6 (Figure 5C; n = 5) and TNFα (Figure 5D; n = 5) were unchanged by exposure to any of the 
biomaterials. 
4. Discussion 
Assessing the potential total blood damage effects of multiple biomaterials in vitro are desired to 
minimise adverse events in VAD patients. Our model has focused on how leukocytes respond to 
the VAD candidate biomaterials to quickly identify which cells are affected. Such a model might 
prove an effective early stage screening tool for evaluating biomaterials. The simple suspension of 
a disc in a petri dish can be performed by anyone and allows for full blood coverage over a large, 
flat, uniform surface – more representative of the implantation of a medical device than thin films, 
wires, and beads used by others [40-42]. Additionally, our model allows for erythrocytes, platelets, 
and leukocytes in whole blood to be studied simultaneously in an experimental system which is 
recommended by the International Standards [43]. A key feature of this model is that the assays 
can be used to quickly identify leukocyte subsets most susceptible to each biomaterial type and 
the level of activation, all of which might contribute to thrombus formation within the VAD [44]. 
The biomaterial discs used in this study were manufactured to have a smooth surface (Table 1) to 
comply with the internal surface condition of many VAD types (MicroMed DeBakey, Jarvik-2000, 
HeartWare HVAD) [20] and were cleaned thoroughly to reduce the presence of contaminants; 
endotoxin levels were below 1 EU/mL (Supplementary Figure 5). The method was designed to 
allow the effects of the biomaterials to emerge without requiring complicated experimental rigs. 
Initial time course analysis revealed that incubation times longer than 2 hours introduced time-
related artefacts, thus more detailed analysis was performed at the 2 h time-point for the rest of the 
study. Activation of blood cells can occur very quickly in response to biomaterials with 
intracellular calcium flux in T cells within 2 minutes [45], and up-regulation of CD11b as early as 
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30 minutes in some studies [46]. However, a 2 h time point allows early stage evaluation and a 
comparison of the biomaterials of interest before progressing to more complex studies 
incorporating experimental conditions, such as shear stress, better representative of the in vivo 
scenario where residence time is transient but repetitive. Importantly, the model used also allows 
the research question to be refined based on these early stage findings. Reasonable volumes of 
blood can be used in this model to reveal functional impact on the cells of interest. Scalable 
experimental approaches and flow cytometry are useful for this purpose.   
The titanium alloy Ti6Al4V is the biomaterial of choice for the VAD body [20] and is therefore 
the largest surface area for blood contact. Titanium can be thrombogenic by promoting the 
formation of a surface protein matrix composed of fibrinogen, thrombin, complement factors, and 
coagulation cascade proteins such as kallikrein that encourages cell activation and adhesion [47]. 
In this study, titanium had no significant effect on the leukocyte count, leukocyte 
activation/aggregation/death indicating that the surface protein matrix formed was relatively inert 
in terms of leukocyte activation/adhesion.  Titanium has been shown to cause high levels of TNFα 
(~600 pg/mL) in PBMCs cultured for 24 h [48] and a reduction in TNFα in MNCs stimulated with 
LPS [49] which was not observed in this study. However, titanium disc implants in rats have shown 
low levels of TNFα (~25 pg/mL), IL-1β (~15 pg/mL) and IL-1α (~100 pg/mL) in the exudate after 
1 h and even 3 h [10] further highlighting the need to test these biomaterials with whole blood 
rather than isolated cells to mimic the in vivo response.  
Ceramic materials such as Sap, SiN and ZTA used in this study are desirable bearing materials due 
to their potential to resist wear damage, their hardness, and wettability [50, 51]. Biocompatibility 
testing of these materials has so far been limited to bone growth [29], tissue implantation [26], or 
protein adsorption [52, 53]. Our study is the first to analyse the effects of these materials on 
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leukocytes using whole blood. We found monocytes were the most affected cell type with a 
significant decrease in number for SiN and ZTA and a decrease in monocyte expression of CD62L 
on Sap and ZTA. Monocytes have considerable quantities of tissue factor on the surface and 
actively aggregate with platelets when stimulated [54]. Our time course studies of tissue factor 
showed that it wasn’t up-regulated on monocytes until 8hrs (data not shown) which was not 
compatible with the optimised time for these experiments. This delayed tissue factor expression 
might also explain the absence of significant monocyte-platelet aggregates despite the apparent 
effects of the biomaterials on the monocytes in particular. Use of these monocyte-activating 
materials as VAD bearings, could lead to the build-up of thrombus such as that seen in the single-
crystal alumina (ruby) bearing of the HeartMate 2 [55, 56] which this model identifies in vitro.  
To overcome biocompatibility issues in mechanically desirable materials, coatings with excellent 
biocompatibility have been introduced. DLC is one such coating which rapidly adsorbs albumin 
and inhibits fibrinogen adsorption [30] therefore strongly reduces platelet adhesion and activation, 
prolongs clotting time, and suppresses complement convertase activation [32]. In this study, DLC 
showed a significant decrease in monocyte count with a decreased monocyte CD62L expression – 
a response like that of the ceramics. DLC has been shown to slightly increase monocyte adhesion 
[57], with DLC coated rather than uncoated Ti6Al4V favouring cell adhesion [58].  
Due to the findings that monocytes are the key leukocyte target type, ongoing work involves 
optimising methods for visualising cells adhered to the biomaterial surface. A limitation of this 
study is the continued contact of the blood cells with the biomaterials when residence time would 
normally be measured in milliseconds rather than hours, and the absence of shear stress. Parallel 
work is considering the additive effects of biomaterials shear stress on leukocyte activation. This 
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is being done using a rheometer and this approach has driven the size of the biomaterials discs 
used and the model optimised for study.   
5. Conclusion 
This simple model can be used by anyone in the blood-contacting devices field to quickly identify 
the cells most affected by materials of choice for better targeted research. Such research could 
include elucidating the mechanism of activation or careful consideration of the cells of interest 
during further in vitro and in vivo testing of the material. The methods used here go beyond the 
tests recommended by the International Standards to include a more thorough investigation of the 
leukocyte response, such as cytokine release. This is important when designing a device for 
patients with a disease characterised by haematological effects on multiple cells types. Our study 
has largely focused on leukocytes and shown that monocytes become activated by ceramic 
materials considered for bearings and DLC, the classically termed ‘inert’ material, but not with 
titanium. Such monocyte activation could contribute to the thrombus build-up which has already 
been observed on ceramic material bearings in current VAD designs so warrants further 
investigation. Overall the candidate materials studied caused little activation of healthy, human 
blood leukocytes. However, the target patient group of people with chronic heart failure have pre-
existing inflammation meaning leukocytes, particularly monocytes, are already activated [59, 60] 
which might render the biomaterials no longer ‘inert’. This possibility has been described: platelet 
adherence on low and medium thrombogenic polymer-based biomaterials was increased for 
patients with coronary artery disease compared to healthy controls [61]. Therefore, this model also 
offers a simple approach to determining the effects of biomaterials leukocytes and other blood 
cells and proteins in blood from paediatric and adult heart failure patients to add real value to the 
field. 
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Figures and Tables 
Table 1. Biomaterial specifications. Surface roughness was measured using a SurfTest SJ-210 
profileometer (Mitutoyo UK) Ltd., Hampshire, UK). 
 
 
 
 
Biomaterial 
Abbreviation 
used 
Ø 
(mm) 
h 
(mm) 
Surface 
area 
(mm²) 
Surface 
roughness (Ra, 
µm) 
Diamond-like carbon 
coated stainless steel 
DLC 60 2 6032 0.774 
Single-crystal 
sapphire 
Sap 60 4 6409 
0.044 
  
Silicon nitride SiN 60 4 6409 0.029 
Titanium alloy 
(TiAl6V4) 
Ti 60 2 6032 0.099 
Zirconia toughened 
alumina 
ZTA 46 3 4072 0.047 
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Table 2. Flow cytometry antibodies. Whole blood (20 µL) was incubated on ice in the dark for 
30 min with antibodies for leukocyte activation (CD15, CD14, CD3, CD62L, CD11b, fMLPr), red 
blood cells were lysed with EasyLyse and then DRAQ7 added before acquisition (lyse-no-wash 
protocol).  
Cell type/ 
activation 
marker 
Antigen Colour Clone Isotype Concentration 
(ng/µL) 
Supplier 
Neutrophil CD15 Krome 
Orange 
80H3 IgM 12.5 Beckman Coulter, 
High Wycombe, UK 
Monocyte CD14 Pacific 
Blue 
M5E2 IgG2a 500 BioLegend, London, 
UK 
T-Lymphocyte  CD3 APC-
AF750 
UCHT1 IgG1κ 100 Beckman Coulter, 
High Wycombe, UK 
L-selectin CD62L PE DREG-56 IgG1κ 25 eBioscience, Hatfield, 
UK 
Macrophage-1 
antigen 
CD11b APC CBRMI/5 IgG1κ 100 eBioscience, Hatfield, 
UK 
Formyl peptide 
receptor 1 
fMLPr FITC REA169 IgG1 220 Miltenyi Biotec, 
Woking, UK 
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Figure 1. The effect of various biomaterials on erythrocytes. Whole heparinised blood was 
exposed to each of the biomaterials - diamond-like carbon coated stainless steel (DLC), single-
crystal sapphire (Sap), silicon nitride (SiN), titanium alloy (Ti), and zirconia toughened alumina 
(ZTA) - for 2 hours and A) complete cell counts were measured on an automated haematology 
analyser (n = 16) and B) plasma-free haemoglobin (pfHB) measured in plasma from whole 
heparinised blood exposed to each of the biomaterials– using the Harboe assay and B) compared 
to time 0 baseline and shown as a fold change (n = 9).  
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Figure 2. The effects of various biomaterials on total leukocyte and subset counts. Whole 
heparinised blood was exposed to each of the biomaterials - diamond-like carbon coated stainless 
steel (DLC), single-crystal sapphire (Sap), silicon nitride (SiN), titanium alloy (Ti), and zirconia 
toughened alumina (ZTA) - for 2 hours and complete cell counts were measured on an automated 
A
C D
B
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haematology analyser. A) Total leukocytes, B) neutrophils, C) monocytes, and D) lymphocyte (n 
= 16); * p ≤ 0.05, ** p ≤ 0.01 on statistical comparison to time 0 baseline. 
 
Figure 3. The effect of various biomaterials on neutrophil and monocyte activation and 
death. Whole heparinised blood was exposed to each of the biomaterials - diamond-like carbon 
coated stainless steel (DLC), single-crystal sapphire (Sap), silicon nitride (SiN), titanium alloy 
(Ti), and zirconia toughened alumina (ZTA) - for 2 hours. Samples were then stained with CD62L, 
CD11b, fMLP receptor (fMLPr), CD15, CD14, and DRAQ7. Leukocyte activation was 
investigated by: A) Change in median fluorescent intensity (MFI) of CD62L on i) CD15+ 
neutrophils (n = 9) and ii) CD14+ monocytes (n = 9); B) Change in percentage of CD11bBright cells 
on i) CD15+ neutrophils and ii) CD14+ monocytes (n = 6); C) Change in percentage of fMLPr on 
i) CD15+ neutrophils and ii) CD14+ monocytes (n = 5); D) Percentage of i) CD15+ neutrophils and 
ii) CD14+ monocytes cells are dead as determined by DRAQ7 (n = 5). All were compared to the 
Di
Cii
Ai
Aii
Bi
Bii
Ci
Dii
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0
5
1 0
1 5
D e a d  N e u tro p h ils
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
(
b
a
s
e
li
n
e
 %
D
R
A
Q
7
+
)
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0
5
1 0
1 5
2 0
2 5
D e a d  M o n o c y te s
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
(
b
a
s
e
li
n
e
 %
D
R
A
Q
7
+
)
1
0
 n
g
/m
L
 L
P
S
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0 .0
0 .5
1 .0
1 .5
2 .0
N e u tro p h il C D 6 2 L  e x p re s s io n
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
(
b
a
s
e
li
n
e
 C
D
6
2
L
 M
F
I)
1
0
 n
g
/m
L
 L
P
S
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0 .0
0 .5
1 .0
1 .5
M o n o c y te  C D 6 2 L  e x p re s s io n
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
(
b
a
s
e
li
n
e
 C
D
6
2
L
 M
F
I)
* ** *
1
0
 n
g
/m
L
 L
P
S
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0
1 0
2 0
3 0
4 0
5 0
N e u tro p h il C D 1 1 b  e x p re s s io n
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
 (
b
a
s
e
li
n
e
 %
C
D
1
1
b
B
r
ig
h
t
 c
e
ll
s
)
1
0
 n
g
/m
L
 L
P
S
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0
5
1 0
1 5
2 0
M o n o c y te  C D 1 1 b  e x p re s s io n
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
 (
b
a
s
e
li
n
e
 %
C
D
1
1
b
B
r
ig
h
t
c
e
ll
s
)
1
0
 n
g
/m
L
 L
P
S
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0
1 0
2 0
3 0
N e u tro p h il fM L P r  e x p re s s io n
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
 (
b
a
s
e
li
n
e
 %
f
M
L
P
r
+
 c
e
ll
s
)
1
0
 n
g
/m
L
 L
P
S
N
e
g
a
t i
v
e
 C
o
n
tr
o
l
D
L
C
S
a
p
S
iN T
i
Z
T
A
0
5
1 0
1 5
M o n o c y te  fM L P r  e x p re s s io n
B io m a te r ia ls
F
o
ld
 c
h
a
n
g
e
 (
b
a
s
e
li
n
e
 %
f
M
L
P
r
+
 c
e
ll
s
)
23 
 
time 0 baseline as a fold change (dashed line). The LPS positive control is indicated with a dotted 
line (* p ≤ 0.05, ** p ≤ 0.01).  
 
 
Figure 4. The effects of various biomaterials on leukocyte-platelet aggregation. Whole 
heparinised blood was exposed to each of the biomaterials - diamond-like carbon coated stainless 
steel (DLC), single-crystal sapphire (Sap), silicon nitride (SiN), titanium alloy (Ti), and zirconia 
toughened alumina (ZTA) - for 2 hours. Samples were then stained with CD14, CD15, and CD41. 
Percentage of dual-positive cells (CD14+/CD41+ or CD15+/CD41+) were compared to the time 0 
baseline as fold change (n = 5).  
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Figure 5. Lipopolysaccharide-stimulated release of cytokines in blood exposed to different 
biomaterials. Whole heparinised blood incubated with various biomaterials - diamond-like carbon 
coated stainless steel (DLC), single-crystal sapphire (Sap), silicon nitride (SiN), titanium alloy 
(Ti), and zirconia toughened alumina (ZTA) - for 2 h was placed into culture either in media alone 
(unstimulated) or with media containing 10 ng/mL LPS (stimulated) for a further 24 h in 5% CO2, 
37°C. Pro-inflammatory cytokines A) IL-8 (n = 7), B) IL-1β (n = 7), C) IL-6 (n = 5), and D) TNFα 
A
C
B
D
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(n = 5) were measured with specific ELISA. No significant difference in comparison to time 0 
baseline although ZTA shows elevated levels of IL-6 and TNF-α in unstimulated samples. 
Supplementary Figure 1. Model set-up. 20 polypropylene beads of 2-3 mm diameter were added 
to a 70 mm petri dish (A&B) in a circle in order to support the biomaterial to allow maximum 
surface area coverage. The biomaterial was carefully laid on top of the beads (C&D) and blood 
(15 mL) added. The dishes were then placed on a shaker plate and incubated at 37°C for 2 hours. 
Supplementary Figure 2. Flow cytometry gating strategy for leukocyte activation, death and 
aggregation. Baseline (time 0 sample) and baseline blood stimulated with 10 ng/mL LPS for 4 
hours (positive control for leukocyte activation) were stained with CD3, CD14, CD15, CD62L, 
CD11b, fMLP receptor (fMLPr), and DRAQ7. Samples were used to set up gating strategy for 
activation profiles of different leukocyte subsets with neutrophils shown in figure. A) Neutrophils 
(CD15+) were identified by plotting SSC/CD15-Krome Orange. CD15+ events were then plotted 
as SSC versus CD62L-PE, CD11b-APC, or fMLPr-FITC. Gates were set according to baseline 
samples having high expression of CD62L, dim expression of CD11b and fMLPr and vice versa 
for LPS samples. B) 1% Triton-X 100 was added to lysed baseline blood, vigorously vortexed, 
and DRAQ7 added before running sample as a dead cell control. DRAQ7 positive events 
(DRAQ7+) identified dead cells and a gate was on these. Baseline was used as a dead cell negative 
control. C) Baseline and baseline blood stimulated for 20 min with 4 µM PMA stained with CD14, 
CD15 and CD41. Platelets were identified using CD41 with neutrophil-platelet aggregates also 
positive for CD15 and monocyte-platelet aggregates also positive for CD14.  
Supplementary Figure 3. The effect of various biomaterials on lymphocyte activation and 
death. Whole heparinised blood was exposed to each of the biomaterials - diamond-like carbon 
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coated stainless steel (DLC), single-crystal sapphire (Sap), silicon nitride (SiN), titanium alloy 
(Ti), and zirconia toughened alumina (ZTA) - for 2 hours. Samples were then stained with CD62L, 
CD3 and DRAQ7. Change in A) median fluorescent intensity (MFI) of CD62L; and B) percentage 
of DRAQ7+ dead cells. There were no significant differences in comparison to baseline (all n = 3). 
Supplementary Figure 4. The effects of various biomaterials on soluble CD62L.  Whole 
heparinised blood was exposed to each of the biomaterials - diamond-like carbon coated stainless 
steel (DLC), single-crystal sapphire (Sap), silicon nitride (SiN), titanium alloy (Ti), and zirconia 
toughened alumina (ZTA) - for 2 hours. Samples were centrifuged and the plasma analysed for 
soluble L-selectin using specific ELISA. There were no significant differences in comparison to 
baseline (n = 8).  
Supplementary Figure 5: Endotoxin levels. Unstimulated, biomaterial-exposed-cell culture 
supernatants were analysed for endotoxin described in the materials and methods (n = 7). 1 EU/mL 
is approximately 0.1 ng endotoxin/mL.  
 
